Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:11:13.556Z.
Consensus retrieved: 2026-10-06T10:00:40.218Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:11:13.556Z.
Quote observation: 2026-10-06T16:10:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9b4bc62a31f75b1a016fc6ea0dc71fcb65437a541a8d62a03c8decabfd044c64
Forward PE Ratio (N/A) = Dated Quote Price ($2.02) / Consensus Forward EPS ($-16.50)
FORWARD PE RATIO
N/A
Cardio Diagnostics Holdings, Inc.
Market Cap
$5.98M
Forward PE Ratio
N/A
Market Cap
$5.66M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | $5.98M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.93M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.91M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.85M | N/A |
| Femasys Inc. (FEMY)vs › | $6.24M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.72M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.71M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.66M | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.40M | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.43M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.02, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-16.50 | $-16.50 – $-16.50 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
